Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficlatuzumab +/- Cetuximab in Cetuximab-Resistant HNSCC
NCT03422536Phase 2Completed
- Sponsor
- University of Arizona
- Start
- Dec 2017
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ficlatuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Arizona. Started Dec 2017; status: completed.
02
Drugs
ficlatuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03422536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422536.